RPG Life Sciences · NSE: RPGLIFE · BSE: 532983
Q2 FY25 results · Jul–Sep 2024
RPG Life Sciences reported revenue from operations of ₹172.21 crore (up 12.1% from Q2 FY24) and net profit of ₹4.20 crore (down 83.8% from Q2 FY24) for Q2 FY25 (Jul–Sep 2024), on a standalone basis.
| Item | Q2 FY25 | Q2 FY24 | YoY | Q1 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 172.21 | 153.58 | +12.1% | 165.42 | +4.1% |
| Other income | 1.94 | 1.83 | +6.0% | 2.37 | −18.1% |
| Total income | 174.15 | 155.41 | +12.1% | 167.79 | +3.8% |
| Profit before tax | 15.09 | 34.79 | −56.6% | 36.00 | −58.1% |
| Net profit for the period | 4.20 | 25.86 | −83.8% | 26.76 | −84.3% |
| EPS, basic (₹) | 2.54 | 15.64 | −83.8% | 16.18 | −84.3% |
| Net margin (%) | 2.4 | 16.8 | 16.2 |
Standalone
- Filed with BSE
- 07 Nov 2024, 18:54 IST
- Board meeting
- 07 Nov 2024
- Period
- 01 Jul 2024 to 30 Sep 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE